Dynepo
epoetin delta
Table of contents
Withdrawn
This medicine is now withdrawn from use in the European Union.
Overview
The marketing authorisation for Dynepo has been withdrawn at the request of the marketing authorisation holder.
This EPAR was last updated on 23/04/2009
Authorisation details
| Product details | |
|---|---|
| Name |
Dynepo
|
| Agency product number |
EMEA/H/C/000372
|
| Active substance |
epoetin delta
|
| International non-proprietary name (INN) or common name |
epoetin delta
|
| Therapeutic area (MeSH) |
|
| Anatomical therapeutic chemical (ATC) code |
B03XA
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Shire Pharmaceutical Contracts Limited
|
| Revision |
9
|
| Date of issue of marketing authorisation valid throughout the European Union |
18/03/2002
|
| Contact address | |
Product information
29/02/2008 Dynepo - EMEA/H/C/000372 - II/0020
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Pharmacotherapeutic group
Antianemic preparations
Therapeutic indication
Therapeutic indication
Dynepo is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult patients. It may be used in patients on dialysis and in patients not on dialysis.